Drug intelligence / Profile preview

SCM-010

Development stage: Discontinued
Lead developer: Stem Cell Medicine
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous, Intrathecal

Overview

SCM-010 is a cell therapy product consisting of adipose-derived expanded mesenchymal stem cells (MSCs), developed by Stem Cell Medicine. It is specifically designed for intrathecal administration to treat secondary progressive multiple sclerosis (SPMS). The therapeutic rationale is based on the ability of MSCs to secrete immunomodulatory factors and neurotrophic agents that can cross the blood-brain barrier more effectively when delivered directly into the cerebrospinal fluid, potentially reducing neuroinflammation and promoting remyelination or axonal protection in patients with advanced MS.

Other names: adipose-derived expanded mesenchymal stem cells SCM-010SCM010SCM-010SCM 010

Beyond the preview

Go deeper on SCM-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCM-010.

Explore the full profile